Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates

By Zacks Investment ResearchStock MarketsApr 27, 2017 10:55PM ET
www.investing.com/analysis/resmed-(rmd)-beats-q3-earnings,-misses-sales-estimates-200186033
ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates
By Zacks Investment Research   |  Apr 27, 2017 10:55PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

ResMed Inc. (NYSE:RMD) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level. Earnings also beat the Zacks Consensus Estimate by a penny.

Including one-time items, ResMed reported EPS of 62 cents in the quarter, down 3.1% year over year.

Revenues in Details

Revenues in the reported quarter increased 13.3% year over year (up 14% at constant exchange rate or CER) to $514.2 million. The figure however missed the Zacks Consensus Estimate of $519.6 million.

ResMed Inc. Price, Consensus and EPS Surprise

ResMed Inc. Price, Consensus and EPS Surprise | ResMed Inc. Quote

On a geographic basis, revenues in the Americas rose 18% year over year to $332.1 million, which included Brightree revenues of $35.0 million. Excluding Brightree, revenues in the Americas totaled $297.1 million, reflecting a 5% increase over the prior year quarter. Revenues in combined EMEA and APAC were $182.1 million, highlighting a 9% rise at CER, compared to the same period last year.

Adjusted gross margin expanded 103 basis points (bps) year over year to 58.3% in the reported quarter. Selling, general and administrative expenses were up 15.5% year over year to $137.8 million, while there was a 24.9% increase in Research and Development expenses to $35.1 million. This led to a 17.3% rise in adjusted operating expenses, which amounted to $172.9 million. Accordingly, adjusted operating margin in the quarter contracted 13 bps to 24.6%.

Financial Update

ResMed exited third-quarter 2017 with cash and cash equivalents of $827.3 million, compared with $788.1 million in the second quarter.

Year to date, the company generated $273.7 million of cash flow from operations, down from the year-ago figure of $404.9 million, displaying weak underlying earnings and a decline in net working capital balances.

Concurrent to its third-quarter earnings release, ResMed announced a quarterly dividend of 33 cents per share, representing a 10% increase from the company’s prior payout. The dividend will be paid on Jun 15, to shareholders of record as on May 11.

As previously declared, ResMed temporarily suspended its share repurchase program due to recent acquisitions. However, the company still expects to recommence the buy-back program sometime in fiscal 2018.

Guidance

Management expects SG&A expenses, as a percentage of revenues, in the band of 26%–27%. R&D expenses, as a percentage of revenues, are projected at 7% for fourth-quarter 2017. This reflects marketing expenses associated with product launches along with the ongoing legal expenses.

Our Take

ResMed exited the third quarter on a mixed note with earnings beating the Zacks Consensus Estimate and sales missing the mark. Challenges like competitive bidding and reimbursement issues continue to plague the stock. Foreign exchange movements dented third-quarter earnings by a penny, thanks to the weaker Euro and stronger Australian dollar relative to the U.S. dollar.

On the bright side, the company achieved solid double-digit global revenue growth this quarter, led by sales from Software-as-a-Service businesses as well as its new mask products. The company also launched the ResMed AirMini during the reported quarter. All these factors boost investor faith in the stock.

Zacks Rank & Key Picks

ResMed currently has a Zacks Rank #4 (Sell). Better-ranked stocks in the broader Medical space include Inogen, Inc. (NASDAQ:INGN) , ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ) and Hill-Rom Holdings, Inc. (NYSE:HRC) . While Inogen and ZELTIQ Aesthetics sport a Zacks Rank #1 (Strong Buy), Hill-Rom carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Inogen gained 53.4% in the last one year, compared with the S&P 500’s gain of 15.6%. The company reported a stellar four-quarter positive average earnings surprise of over 49.08%.

ZELTIQ Aesthetics surged 88.9% in the last one year, in comparison to the S&P 500. Its four-quarter average earnings surprise was a positive 12.03%.

Hill-Rom gained over 52.7% in the past one year, better than the S&P 500 mark. It posted a trailing four-quarter positive average earnings surprise of 3.1%.

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>



Inogen, Inc (INGN): Free Stock Analysis Report

ResMed Inc. (RMD): Free Stock Analysis Report

Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report

ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report

Original post

Zacks Investment Research
ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates
 

Related Articles

ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email